# A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

> **NCT06041516** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (estimated)

## Conditions studied

- Neuroendocrine Carcinomas
- Neuroendocrine Tumors
- Carcinoma, Neuroendocrine
- Carcinoma, Adrenocortical
- Carcinoma, Adrenal Cortical

## Interventions

- **DRUG:** ADCT-701

## Key facts

- **NCT ID:** NCT06041516
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2027-10-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041516, "A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT06041516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*